New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
September 10, 2013
10:17 EDTCTRX, ESRXAnalyst says Express Scripts won't be hurt by private exchanges
Express Scripts (ESRX), which provides pharmacy benefit management services, is unlikely to be significantly hurt by private health insurance exchanges, research firm Jefferies believes. Investor worries about the impact of such exchanges on the company is overdone, the firm added. WHAT'S NEW: Following reports yesterday that several major companies are looking to place their retired workers into a private health insurance exchange, Jefferies analyst Brian Tanquilut wrote that such exchanges have been around for several years and have not significantly affected Express Scripts or its competitors. Moreover, many investors do not realize that Express Scripts' profit margins from the exchanges are not much lower than its margins from the large companies, Tanquilut contended. Finally, as a result of the shift of beneficiaries onto private exchanges, Express Scripts will have the opportunity to win new customers currently covered by its competitors, the analyst believes. He expects the stock to start advancing in the fourth quarter of this year and kept a Buy rating on the shares. WHAT'S NOTABLE: Express Scripts' stock fell slightly in an up market yesterday, as did shares of its competitor Catamaran (CTRX). TODAY'S PRICE ACTION: In early trading today, Express Scripts added 0.5% to $65 and Catamaran rose 0.45% to $45.60
News For ESRX;CTRX From The Last 14 Days
Check below for free stories on ESRX;CTRX the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 15, 2014
10:00 EDTCTRXOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
07:20 EDTCTRXCatamaran upgraded to Outperform from Perform at Oppenheimer
Subscribe for More Information
April 14, 2014
15:02 EDTCTRXCatamaran Mat volatility increases, shares near two-year low
Subscribe for More Information
11:09 EDTCTRXOptions with increasing implied volatility: HZNP VJET YOKU CTRX CBS
08:02 EDTCTRXCatamaran recent sell-off overdone, says Jefferies
Jefferies views the recent sell-off in shares of Catamaran as overdone. The firm attributes the move to concerns about the company's ability to meet Q1 consensus and win new contracts. Jefferies expects Catamaran shares to bounce back to the mid-$40s soon after the Q1 report and it keeps a Buy rating on the stock.
April 10, 2014
14:27 EDTCTRXCatamaran sell-off overdone, says UBS
Subscribe for More Information
09:23 EDTCTRXCatamaran channel checks cautious, says Cleveland Research
Cleveland Research said Catamaran checks indicate client frustration with customer service and implementation issues. The firm sees downside to 2014 estimates from higher expenses, system upgrades and potential to pay performance guarantees.
April 9, 2014
11:43 EDTESRXGilead defended by analysts after recent pullback
Subscribe for More Information
08:41 EDTESRXAttack on Gilead Sovaldi by Express Scripts 'noise,' says Maxim
After Bloomberg reported that Express Scripts (ESRX) said that it would attempt to build a coalition against the use of Gilead's (GILD) Sovaldi once a rival drug is approved, Maxim views Express Scripts' statement as "noise." The firm says that Sovaldi is not the most expensive HCV drug, and reiterates its view that Sovaldi provides "compelling" value, when including the cost of failure rates in a cost/benefit analysis. Maxim keeps a Buy rating on Gilead.
April 7, 2014
07:44 EDTCTRXMarketo to hold a summit
Subscribe for More Information
April 4, 2014
10:53 EDTCTRX High option volume stocks: ITW CTRX WMC LQD IMGN
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use